Resultado de búsqueda
17 de jun. de 2024 · Marinus Pharmaceuticals today announced topline results from the Phase 3 double-blind, randomized, placebo-controlled RAISE trial (NCT04391569) evaluating the safety and efficacy of intravenous (IV) ganaxolone for the treatment of refractory status epilepticus (RSE).
15 de jun. de 2024 · Marinus Pharmaceuticals is a clinical stage biopharmaceutical company. It is engaged in the development and commercialization of ganaxolone. The Company develops treatments for patients suffering from drug-resistant seizures and neuropsychiatric disorders.
17 de jun. de 2024 · Marinus will continue to prioritize the ZTALMY ® franchise and expansion opportunities in highly refractory, chronic epilepsies with Phase 3 TrustTSC topline data expected in the first half of Q4...
17 de jun. de 2024 · The failure of Marinus' trial for ganaxolone in RSE has left it facing the prospect of a new study to keep its hope alive in the indication.
17 de jun. de 2024 · Marinus expects to present the RAISE data at an upcoming medical meeting. Marinus intends to continue to offer IV ganaxolone for patients with super refractory status epilepticus under emergency investigational new drug applications.
18 de jun. de 2024 · US-based pharmaceutical company Marinus Pharmaceuticals has reported topline results from the Phase III RAISE clinical trial of intravenous (IV) ganaxolone for treating RSE. The double-blind,...
Hace 4 días · Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders.
